The Relation of Initial Methimazole Dose to the Incidence of Methimazole-induced Agranulocytosis in Patients with Graves Disease
|
|
- Julius Craig
- 5 years ago
- Views:
Transcription
1 Endocrine Journal 2007, 54 (1), The Relation of Initial Methimazole Dose to the Incidence of Methimazole-induced Agranulocytosis in Patients with Graves Disease KUMIKO TSUBOI, HAJIME UESHIBA, MASAKO SHIMOJO, MAYUMI ISHIKAWA, NATSUKO WATANABE, KAORU NAGASAWA, RENA YUASA AND GEN YOSHINO Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University School of Medicine, , Omori-nishi, Ota-ku, Tokyo , Japan Abstract. The relation between the incidence of methimazole (methylmercaptoimidazole; MMI)-induced agranulocytosis and initial MMI dose was evaluated in a group of 514 patients with Graves disease who were treated between 1995 and One hundred and forty-six (28.40%) patients had received an initial dose of 30 mg MMI and 277 (53.89%) patients had been treated with 15 mg MMI. Nine patients (1.75%) developed agranulocytosis due to MMI treatment. Six (4.11%) of 146 patients who received an initial dose of 30 mg MMI, two (4.54%) of 44 patients given an initial dose of 20 mg MMI, and one (0.36%) of 277 patients given an initial dose of 15 mg MMI developed agranulocytosis. There was a statistically significant difference in agranulocytosis incidence between patients receiving an initial dose of 30 mg MMI and those who received an initial dose of 15 mg. Although 8 (4.10%) of 195 patients in the high-dose group (20 mg or higher) developed agranulocytosis, only 1 (0.31%) of 319 patients in the low-dose group (15 mg or lower) did. In conclusion, the incidence of agranulocytosis with low-dose MMI therapy was ten times lower than that of the high-dose regimen. Key words: Antithyroid-drug, ATD, Agranulocytosis, Graves disease, MMI, Methimazole, Methylmercaptoimidazole (Endocrine Journal 54: 39 43, 2007) AGRANULOCYTOSIS is a potentially fatal side effect of the antithyroid drugs (ATD) that are widely used for the treatment of Graves disease. Shirooze et al. [1] and Okamura et al. [2] reported that the effectiveness of low-dose methimazole (methylmercaptoimidazole; MMI) for the treatment of hyperthyroidism was no less than that of 30 mg MMI. In addition, a European prospective randomized study [3] reported that 10 mg and 40 mg MMI regimens were equally effective. Before 1994, when the standard initial dose of MMI was 30 mg, MMI-induced agranulocytosis was a not uncommon, extremely serious, adverse effect. Received: May 30, 2005 Accepted: September 4, 2006 Correspondence to: Dr. Kumiko TSUBOI, Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University School of Medicine, , Omori-nishi, Ota-ku, Tokyo , Japan After implementing a low-dose MMI regimen, patients given an initial dose of 15 mg MMI only rarely developed agranulocytosis. We examined records of patients with Graves disease to determine the incidence of MMI-induced agranulocytosis and to identify any association with dose. Patients and Methods We analyzed the incidence of MMI-induced agranulocytosis by reviewing the records of patients with Graves disease treated at the thyroid clinics of Toho University Oomori Hospital from 1995 to A diagnosis of Graves disease was based on clinical findings, laboratory tests, and the Japan Thyroid Association s guidelines for the diagnosis of Graves disease [4]. Patients who were referred to our clinic after surgery or 131 I therapy, some of whom had agranulocytosis,
2 40 TSUBOI et al. were excluded from the study. Agranulocytosis was defined as a circulating neutrophil count lower than 500/µL. Statistical analysis Analysis of population proportions was performed using Fisher s exact test. Statistical significance was defined as P<0.05. Results A total of 772 patients were diagnosed as having Graves disease between 1995 and Of these, 514 patients with hyperthyroidism were treated with MMI. One hundred and forty-six patients (28.40%) had received an initial dose of 30 mg MMI, and 277 patients Table 1. Initial dose of MMI Initial MMI dose and incidence of MMI-induced agranulocytosis in patients with Graves disease Number of patients Number who developed agranulocytosis Incidence (%) 60 mg mg mg mg mg mg mg mg Total (53.89%) had received 15 mg MMI. Nine (1.75%) of these 514 patients developed agranulocytosis due to MMI. Six (4.11%) of the 146 patients who received an initial dose of 30 mg MMI developed agranulocytosis, as did 2 (4.54%) of 44 patients at 20 mg MMI and 1 (0.36%) of 277 at 15 mg MMI. All patients with agranulocytosis had clinical signs and symptoms of infection. Table 1 shows the total number of patients and the number of patients who developed agranulocytosis at each initial dose point. The clinical data of the 9 patients who developed agranulocytosis due to MMI, including the initial dose of MMI, the duration of MMI therapy, leukocyte count (WBC), neutrophil count, and patient outcome, are summarized in Table 2. Of particular importance is that 5 of the 9 patients who developed agranulocytosis had voluntarily interrupted medical treatment (indicated by * in Table 2). There was a statistically significant difference in agranulocytosis incidence between patients receiving 30 mg MMI and those receiving 15 mg MMI. If we define an initial dose of 20 mg or higher as the high-dose group and an initial dose of 15 mg or lower as the low-dose group, 8 (4.10%) of the 195 patients in the high-dose group developed agranulocytosis and only 1 (0.31%) of the 319 patients in the low-dose group developed agranulocytosis. The difference between the high-dose and lowdose groups was statistically significant. Discussion Although the incidence of agranulocytosis with lowdose MMI was one-tenth that of the high-dose regimen, Table 2. Clinical characteristics and outcome of patients with Graves disease complicated by MMI-induced agranulocytosis # Year of the onset Sex/Age MMIdose mg/d * Duration (weeks) WBC counts Neutrophil counts Treatment for agranulocytosis Outcome F/44 30 * 3** G-CSF PTU M/42 30 * 6** G-CSF RI M/ W/o G-CSF Surgery F/18 20 * 10** G-CSF RI F/ G-CSF RI M/62 30 * 4** G-CSF Surgery F/26 30 * W/o G-CSF PTU F/ ** 1) G-CSF RI F/ G-CSF Surgery Duration: Duration of MMI therapy at the time of agranulocytosis onset; *: Medication had been voluntarily discontinued, then resumed; **: Duration after resumption of therapy; 1): MMI dose was 30 mg 11 days, then 15 mg 20 days; G-CSF: Granulocyte colony-stimulating factor; W/o G-CSF: without G-CSF therapy; PTU: Propylthiouracil; RI: Radioiodine ( 131 I) therapy
3 AGRANULOCYTOSIS AND MMI 41 the clinical effectiveness of the regimens was similar [1 3, 5], suggesting that there is no longer a convincing rationale for continuing high-dose MMI. Despite convincing evidence for the effectiveness of low-dose MMI, many patients referred to our clinic had been placed on high-dose MMI, perhaps because Japanese reference books recommend an initial dose of 30 mg. We do not have data for the other major antithyroid drug, propylthiouracil (PTU), because it is not our first choice for treatment of Graves disease. When fever or infection develops, many patients who initially receive treatment at clinics are referred to a general hospital or medical center such as our university hospital. Our hospital therefore receives an unrepresentative percentage of more serious cases. To avoid such hospital bias, dropout cases from other clinics were not included in this report. ATD-induced agranulocytosis is comparatively rare, and is less common than other adverse effects, such as skin rash and itchiness. The Noguchi Thyroid Clinic and Hospital Foundation [6] reported that the incidence of agranulocytosis was 0.31% in 13,208 Graves disease cases with a mean dosage of 27.8 ± 8.9 mg/d. Because a minimum of 1000 to 5000 patients is necessary to determine the incidence of relatively rare adverse effects, our sample size was insufficient to calculate accurately the incidence of agranulocytosis. Tajiri et al. [7] studied the largest collection of Graves disease cases, 30,798 patients, and found that the incidence of ATD-induced agranulocytosis was 0.35%; our overall incidence of 1.75% (9 of 514) was much higher. Although we are unable to explain this relatively high incidence, we were able to analyze differences between a high-dose group and low-dose group. It has been suggested that high doses of MMI are associated with development of agranulocytosis. ATD-induced agranulocytosis, however, is not a result of dose-related toxicity. It might be caused by an immune mechanism that tends to occur relatively early in the course of medical treatment with drugs to which patients have been previously exposed. In our experience, voluntary discontinuation of medical treatment is not exceptional. Indeed, in the present study, 5 of the 9 patients who suffered agranulocytosis had undergone re-treatment with MMI. We believe that this repeated exposure may be a risk factor for MMI-induced agranulocytosis. The mechanisms responsible for the agranulocytosis are unclear, but cellular autoimmunity may be involved in its development. Positive associations between HLA class II allele and agranulocytosis were observed [8], many antibodies such as anti-leukocyte antibodies and anti-granulocyte antibodies have been proposed. PTU-induced autoimmune disease was known as PTU-induced lupus-like syndrome, PTU is also known as a trigger for antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Recently, complement-mediated cytotoxicity was postulated as a mechanism of PTU-induced ANCA-positive neutropenia [9]. ANCA specific for proteinase 3 (PR3) and myeloperoxidase (MPO) are associated with necrotizing vasculitis, and ANCA-activated neutrophils contribute to oxidative and proteolytic damage of blood vessels [10]. Priming (TNF-alpha)-induced translocation of PR3 and MPO to the cell surface may induce cytotoxicity [9]. ANCA-associated vasculitis and ATD-associated ANCA-positive patients in Belgrade were reported [11]. In this 11-year retrospective study, they obtained 72 patients with PR3-ANCA or MPO-ANCA positive, 16/72 (22.3%) patients developed symptoms of systemic disease during ATD therapy. PTU is a very common trigger for ANCA, and 12 of these 16 were induced by PTU. There were only 2 patients showed leukopenia (< /l) among the clinically and serologically ANCA-positive ATDtreated patients [11]. Among the 16 patients, ANCA developed or was detected after more than a year of ATD therapy. The duration of ATD therapy in their study is much longer than that in our cases of MMIinduced agranulocytosis. In a series of 18 cases, Dai et al. [12] reported that ATD-induced agranulocytosis developed 2 to 12 weeks after treatment, which is an interval similar to the 4 to 10 weeks observed in our cases. Slight leukopenia and neutropenia are frequent events in thyrotoxicosis before treatment with ATD. Granulocyte colony-stimulating factor (G-CSF) is one of the hematopoietic cytokines, which stimulates granulocyte proliferation and activation. Serum G-CSF levels in untreated patients with Graves hyperthyroidism were higher than those of healthy control [13], or were not different from normal subjects [14]. At least deficiency of G-CSF does not appear to be a cause of agranulocytosis by ATD. Although recombinant human G-CSF (rhg-csf) is clinically applicable for patients with agranulocytosis and GM-CSF use resulted in faster restoration [12], the recovery time in the G-CSF-treated group did not differ from that of the untreated group [15].
4 42 TSUBOI et al. Cooper et al. [16] reported that patients given an MMI dose of 40 mg or higher had an 8.6-fold higher risk of agranulocytosis than did patients receiving lower doses. Furthermore, they reported that no patients given an MMI dose lower than 30 mg/day developed agranulocytosis. In the present study, no patients given an MMI dose lower than 15 mg/d developed agranulocytosis in the period from January 1995 to September In October 2004, however, one patient developed agranulocytosis after a 6-week regimen of 15 mg MMI (Case #9 in Table 2). Tajiri et al. [5] reported that MMI dosage at the time patients developed agranulocytosis ranged from 5 to 45 mg. Because we elected to focus on the initial dose of MMI, our results are not directly comparable with those of this earlier study. A European prospective randomized study [3] of 309 patients reported that 10 mg and 40 mg MMI regimens were equally effective; however, the rate of adverse drug reactions was 15.5% in the 10 mg group and 26.0% in the 40 mg group. They reported that one patient in the 10 mg group had granulocytopenia (<2000/ µl), and one patient in the 40 mg group had agranulocytosis; however, their sample size was not large enough to determine an association with dose. Our sample size is similar and lacked the statistical power to determine conclusively the incidence of MMIinduced agranulocytosis; one patient who received an initial dose of 15 mg MMI did develop agranulocytosis, and this increased the incidence from zero to 0.36%. Although there are no prospective controlled studies confirming the safety of low-dose MMI therapy with respect to agranulocytosis, our findings strongly suggest that the incidence of agranulocytosis is much lower in a low-dose (15 mg/d or less) MMI regimen than in a high-dose regimen. Acknowledgements The authors thank David Kipler, English Language Section, Toho University Faculty of Medicine, for his assistance in preparing the manuscript for publication and Chiaki Nishimura, Ph D., Toho University Faculty of Medicine, for his assistance with the statistical analysis. References 1. Shirooze A, Okamura K, Ikenoue H, Sato K, Nakashima T, Yoshinari M, Fujishima M, Yoshizumi T (1986) Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 63: Okamura K, Ikenoue H, Shirooze A, Sato K, Yoshinari M, Fujishima M (1987) Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves hyperthyroidism. J Clin Endocrinol Metab 65: Reinwein D, Benker G, Lazarus JH, Alexander WD, The European multicenter study group on antithyroid drug treatment (1993) A prospective randomized trial of antithyroid drug dose in Graves disease therapy. J Clin Endocrinol Metab 76: Guidelines for the diagnosis of Graves disease. The Japan Thyroid Association home page, umin.ac.jp. 5. Mashio Y, Beniko M, Matsuda A, Koizumi S, Matsuya K, Mizumoto H, Ikota A, Kunita H (1997) Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr J 44: Tajiri J, Noguchi S, Murakami T, Murakami N (1990) Antithyroid drug-induced agranulocytosis. Usefulness of routine white blood cell count monitoring. Arch Intern Med 150: Tajiri J, Noguchi S (2004) Some patients with antithyroid drug-induced agranulocytosis have normal white blood cell counts. Thyroid 14: Tamai H, Sudo T, Kimura A, Mukuta T, Matsubayashi S, Kuma K, Nagataki S, Sasazuki T (1996) Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves Disease. Ann Intern Med 124: Akamizu T, Ozaki S, Hiratani H, Uesugi H, Sobajima J, Hataya Y, Kanamoto N, Saijo M, Hattori Y, Moriyama K, Ohomori K, Nakao K (2002) Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol 127: Reumaux D, Duthilleul P, Roos D (2004) Pathogenesis of disease associated with antineutrophil cytoplasmic autoantibodies. Hum Immunol 65: Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M (2005) Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune disease induced by antithyroid drugs: comparison with idiopathic ANCA
5 AGRANULOCYTOSIS AND MMI 43 vasculitis. Arthr Res Ther 7: Dai Wei-Xin, Zhang Jian-De, Zhan Shi-Wei, Xu Bao- Zhen, Jin Hong, Yao Yang, Xin Wei-Chang, Bai Yao (2002) Retrospective analysis of 18 case of antithyroid drug (ATD)-induced agranulocytosis. Endocr J 49: Iitaka M, Yoshimura-Noh J, Kitahama S, Fukasawa N, Miura S, Kawakami Y, Kawasaki S, Yamanaka K, Ishii J, Katayama S, Ito K (1998) Elevated serum granulocyte colony-stimulating factor levels in patients with Graves disease. Clin Endocrinol 48: Murakami Y, Sasaki I, Hiraiwa T, Arishima T, Ito M, Hanafusa T, Sakane S, Ohsawa N, Takamatsu J, Miyauchi A, Kuma K (2004) Serum concentrations of granulocyte colony-stimulating factor (G-CSF) in antithyroid drug-induced agranulocytosis. Endocr J 51: Fukata S, Kuma K, Sugawara M (1999) Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug induced agranulocytosis: A prospective study. Thyroid 9: Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway C (1983) Agranulocytosis associated with antithyroid drugs. Ann Intern Med 98:
Thionamide Associated Agranulocytosis: Low Incidence with Low Doses of Methimazole
Int J Endocrinol Metab 2006; 4: 210-215 Thionamide Associated Agranulocytosis: Low Incidence with Low Doses of Methimazole ORIGINAL ARTICLE Bahrami A. Division of Endocrinology and Metabolism, Department
More informationChung-Huei Huang, MD; Kay-Lun Li, MD; Jin-Hou Wu 1, MD; Po-Nan Wang 1, MD; Jyuhn-Huarng Juang, MD
Original Article 242 Antithyroid Drug-induced Agranulocytosis: Report of 13 Cases Chung-Huei Huang, MD; Kay-Lun Li, MD; Jin-Hou Wu 1, MD; Po-Nan Wang 1, MD; Jyuhn-Huarng Juang, MD Background: Antithyroid
More informationAntithyroid drugs induced agranulocytosis and multiple myeloma: case report and general considerations
, pp.327-331 Antithyroid drugs induced agranulocytosis and multiple myeloma: case report and general considerations Dănciulescu Miulescu R*, Carșote M*, Trifănescu R* **, Ferechide D*, Poiană C* ** * Carol
More informationSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, The Medical City, Philippines
Original Article JAFES The Effects of GCSF on the Recovery Time and Duration of Hospitalization in Patients with Anti-thyroid Drug-Induced Agranulocytosis in a Tertiary Hospital Maria Monina Clauna-Lumanta,
More informationClinical Characteristics of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Caused by Antithyroid Drugs
ORIGINAL Endocrine ARTICLE Care Clinical Characteristics of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Caused by Antithyroid Drugs Jaeduk Yoshimura Noh, Shigemitu Yasuda,
More informationCarbimazole Induced Aplastic Anaemia
University Journal of Medicine and Medical Specialities Volume 1 Issue 1 2015 Carbimazole Induced Aplastic Anaemia Anand Zachariah Suvir Singh CHRISTIAN MEDICAL COLLEGE, VELLORE Abstract: Drug induced
More informationJun Yang, 1 Jun Zhang, 1 Qin Xu, 1 Guo-ping Sheng, 2 Wan-wen Weng, 1 and Meng-jie Dong Background
International Endocrinology Volume 2015, Article ID 934726, 6 pages http://dx.doi.org/10.1155/2015/934726 Clinical Study Unusual Synchronous Methimazole-Induced Agranulocytosis and Severe Hepatotoxicity
More informationSUMIHISA KUBOTA, HIDEMI OHYE, GENICHIRO YANO, EIJUN NISHIHARA, TAKUMI KUDO, MITSURU ITO, SHUJI FUKATA, NOBUYUKI AMINO, KANJI KUMA AND AKIRA MIYAUCHI
Endocrine Journal 2006, 53 (5), 603 607 Two-day Thionamide Withdrawal prior to Radioiodine Uptake Sufficiently Increases Uptake and does not Exacerbate Hyperthyroidism Compared to 7-day Withdrawal in Graves
More informationCase Report Methimazole Associated Neutropenia in a Preterm Neonate Treated for Hyperthyroidism
Case Reports in Endocrinology Volume 2015, Article ID 680191, 5 pages http://dx.doi.org/10.1155/2015/680191 Case Report Methimazole Associated Neutropenia in a Preterm Neonate Treated for Hyperthyroidism
More informationRheumatologic Lab Tests
Rheumatologic Lab Tests What the Practitioner Needs to Know Mary Nakamura M.D. 2008 Rheumatologic Lab Tests Are rarely diagnostic of any specific disease If you do not have in mind a rheumatologic disease
More informationStine Linding Andersen, Jørn Olsen, and Peter Laurberg
ORIGINAL ARTICLE Antithyroid Drug Side Effects in the Population and in Pregnancy Stine Linding Andersen, Jørn Olsen, and Peter Laurberg Departments of Endocrinology (S.L.A., P.L.) and Clinical Biochemistry
More informationSutin Sriussadaporn, Wanwaroon Pumchumpol, Raweewan Lertwattanarak, and Tada Kunavisarut
Hindawi International Endocrinology Volume 217, Article ID 2619695, 6 pages https://doi.org/1.1155/217/2619695 Clinical Study Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage
More informationof Graves' Disease Associated with Painful itis
Endocrine Journal 1997, 44 (4), 611-616 NOTE A Case Thyroid of Graves' Disease Associated with Painful itis SHIGENORI NAKAMURA, YUKIE SAIO, AND MASATOSHI ISHIMORI Department of Internal Medicine, Gifu
More informationLong-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
Rheumatology 2008;47:1515 1520 Advance Access publication 1 August 2008 doi:10.1093/rheumatology/ken321 Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated
More informationDiscussion. Case conference. Anemia. The basic evaluation of a patient newly diagnosed with anemia. Speaker : R2 趙劭倫 Supervisor : VS 林立偉
Case conference Discussion Speaker : R2 趙劭倫 Supervisor : VS 林立偉 990123 The basic evaluation of a patient newly diagnosed with anemia Anemia CBC Reticulocyte count : reflects activity in the bone marrow
More informationClinical Characteristics of 852 Patients with Subacute Thyroiditis before Treatment
ORIGINAL ARTICLE Clinical Characteristics of 852 Patients with Subacute Thyroiditis before Treatment Eijun Nishihara, Hidemi Ohye, Nobuyuki Amino, Kazuna Takata, Takeshi Arishima, Takumi Kudo, Mitsuru
More informationSlide notes: This presentation provides information on Graves disease, a systemic autoimmune disease. Epidemiology, pathology, complications,
1 This presentation provides information on Graves disease, a systemic autoimmune disease. Epidemiology, pathology, complications, including ophthalmic complications, treatments (both permanent solutions
More informationOriginal. Akira Kurozumi, Yosuke Okada, Tadashi Arao, Manabu Narisawa, Keiichi Torimoto, Sunao Yamamoto and Yoshiya Tanaka
Endocrine Journal 2015, 62 (1), 69-75 Original Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves disease and type 1 diabetes mellitus:
More informationTitle guidelines: viewpoints from Japan a. Citation Thyroid, 21(6), pp ; Issue Date
NAOSITE: Nagasaki University's Ac Title Author(s) The American Thyroid Association an Endocrinologists hyperthyroidism an guidelines: viewpoints from Japan a Yamashita, Shunichi; Amino, Nobuyuk Citation
More informationThe Use of Iodine as First Line Therapy in Graves' Disease Complicated with Neutropenia at First Presentation in a Paediatric Patient
British Journal of Medicine & Medical Research 3(2): 324-328, 2013 SCIENCEDOMAIN international www.sciencedomain.org The Use of Iodine as First Line Therapy in Graves' Disease Complicated with Neutropenia
More informationTreatment and management of thyroid storm: analysis of the nationwide surveys
Clinical Endocrinology (2016) 84, 912 918 doi: 10.1111/cen.12949 ORIGINAL ARTICLE Treatment and management of thyroid storm: analysis of the nationwide surveys The taskforce committee of the Japan Thyroid
More informationRatio of Serum Free Triiodothyronine to Free Thyroxine in Graves Hyperthyroidism and Thyrotoxicosis Caused by Painless Thyroiditis
Endocrine Journal 2005, 52 (5), 537 542 Ratio of Serum Free Triiodothyronine to Free Thyroxine in Graves Hyperthyroidism and Thyrotoxicosis Caused by Painless Thyroiditis JAEDUK YOSHIMURA NOH, NAOKO MOMOTANI*,
More informationThyrotoxicosis in Pregnancy: Diagnose and Management
Thyrotoxicosis in Pregnancy: Diagnose and Management Yuanita Asri Langi email: meralday@yahoo.co.id Endocrinology & Metabolic Division, Internal Medicine Department, Prof.dr.R.D. Kandou Hospital/ Sam Ratulangi
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated inflammation
More informationanti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid
Online publication June 24, 2009 ANCA JMAAV 1 2 ANCA JMAAV MPO-ANCA 18 17 50 J Jpn Coll Angiol, 2009, 49: 53 61 anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide,
More informationUse of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves disease
European Journal of Endocrinology (2002) 146 173 177 ISSN 0804-4643 CLINICAL STUDY Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of
More informationAntithyroid drugs in Graves disease: Are we stretching it too far?
Original Article Antithyroid drugs in Graves disease: Are we stretching it too far? Muthukrishnan Jayaraman, Anil Kumar Pawah, C. S. Narayanan 1 Department of Internal Medicine, Armed Forces Medical College,
More informationVasculitis local: systemic
Vasculitis Inflammation of the vessel wall. Signs and symptoms: 1- local: according to the involved tissue 2- systemic:(fever, myalgia, arthralgias, and malaise) Pathogenesis 1- immune-mediated 2- infectious
More informationRELATIONSHIP BETWEEN THE EFFECTIVENESS OF INORGANIC IODINE AND THE SEVERITY OF GRAVES THYROTOXICOSIS: A RETROSPECTIVE STUDY
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationClinical Study Lithium Carbonate in the Treatment of Graves Disease with ATD-Induced Hepatic Injury or Leukopenia
Hindawi Publishing Corporation International Journal of Endocrinology Volume 2015, Article ID 694023, 7 pages http://dx.doi.org/10.1155/2015/694023 Clinical Study Lithium Carbonate in the Treatment of
More informationChanges in Serum TSH Receptor Antibody (TRAb) Values in Patients with Graves Disease after Total or Subtotal Thyroidectomy
Endocrine Journal 2003, 50 (5), 595 601 Changes in Serum TSH Receptor Antibody (TRAb) Values in Patients with Graves Disease after Total or Subtotal Thyroidectomy YUUKI TAKAMURA, KEIICHI NAKANO, TAKASHI
More informationCase report. Antithyroid drug induced a granulocytosis: what still we need to learn? Open Access
Case report Open Access Antithyroid drug induced a granulocytosis: what still we need to learn? Liaqat Ali Chaudhry 1,&, Khalid Fouad Mauzen 2, Ebtesam Ba-Essa 3, Asirvatham Alwin Robert 4 1 Department
More informationHaifeng Hou, 1,2,3,4 Shu Hu, 5 Rong Fan, 5 Wen Sun, 5 Xiaofei Zhang, 6 and Mei Tian 1,2,3,4. 1. Introduction
BioMed Research International Volume 2015, Article ID 974689, 4 pages http://dx.doi.org/10.1155/2015/974689 Clinical Study Prognostic Value of 99m Tc-Pertechnetate Thyroid Scintigraphy in Radioiodine Therapy
More informationGraves' Disease: Report of Two Adul. Citation Acta medica Nagasakiensia. 2000, 45
NAOSITE: Nagasaki University's Ac Title Author(s) Antineutrophil Cytoplasmic Antibody Graves' Disease: Report of Two Adul Sera, Nobuko; Yokoyama, Naokata; Ab Toshirou; Tominaga, Tan; Ejima, Eri Kiyoto;
More informationANTITHYROID drugs (methimazole and propylthiouracil)
0021-972X/98/$03.00/0 Vol. 83, No. 3 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Effect of Methimazole, with or without L-Thyroxine, on Remission
More informationThyroglobulin Autoantibodies Are Associated with Refractoriness to Antithyroid Drug Treatment for Graves Disease
ORIGINAL ARTICLE Thyroglobulin Autoantibodies Are Associated with Refractoriness to Antithyroid Drug Treatment for Graves Disease Masahito Katahira 1,2 and Hidetada Ogata 2 Abstract Objective The recurrence
More informationLecture title. Name Family name Country
Lecture title Name Family name Country Nguyen Thy Khue, MD, PhD Department of Endocrinology HCMC University of Medicine and Pharmacy, MEDIC Clinic Hochiminh City, Viet Nam Provided no information regarding
More informationUpdate In Hyperthyroidism
Update In Hyperthyroidism CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright
More informationFour Cases of Graves Disease which Developed after Painful Hashimoto s Thyroiditis
ORIGINAL ARTICLE Four Cases of Graves Disease which Developed after Painful Hashimoto s Thyroiditis Hidemi Ohye 1, Eijun Nishihara 1, Ichiro Sasaki 1, Sumihisa Kubota 1, Shuji Fukata 1, Nobuyuki Amino
More informationPulmonary haemorrhage and vasculitis in Graves disease
Pulmonary haemorrhage and vasculitis in Graves disease L. Leelarathna 1 J. Karalliede 1 C. Kosky 2 D. D Cruz 3 P.V. Carroll 1 Case history A 30 yr old female nurse of African Caribbean descent presented
More informationRelationship between Leukopenia and Bone Marrow Myeloperoxidase in the Rat Treated with Propylthiouracil
Relationship between Leukopenia and Bone Marrow Myeloperoxidase in the Rat Treated with Propylthiouracil Kimio KARIYA, Eibai LEE and Masaaki HIROUCHI Department of Pharmacology, Faculty of Pharmaceutical
More informationThyroid Disease in Pregnancy. Justin Moore, MD
Thyroid Disease in Pregnancy Justin Moore, MD Case 1 22 yr old G1P0 female at 14 2/7 weeks presents with tremor Weight stable since first positive pregnancy test Some nausea, rare vomiting TSH 0.02 miu/l,
More informationSystemic Management of Graves Disease. Robert James Graves, M.D., FRCS ( ) Graves Disease: Endocrinopathy or Ophthalmopathy?
Systemic Management of Graves Disease Rona Z. Silkiss, M.D., FACS Associate Clinical Professor, UCSF Chief, Division of Ophthalmic Plastic and Orbital Surgery California Pacific Medical Center No financial
More informationPredicting relapse of Graves' disease following treatment with antithyroid drugs
EXPERIMENTAL AND THERAPEUTIC MEDICINE 11: 1453-1458, 2016 Predicting relapse of Graves' disease following treatment with antithyroid drugs LIN LIU 1, HONGWEN LU 1, YANG LIU 2, CHANGSHAN LIU 1 and CHU XUN
More informationThe Immune System. A macrophage. ! Functions of the Immune System. ! Types of Immune Responses. ! Organization of the Immune System
The Immune System! Functions of the Immune System! Types of Immune Responses! Organization of the Immune System! Innate Defense Mechanisms! Acquired Defense Mechanisms! Applied Immunology A macrophage
More informationTapazole Methimazole Tablets, USP DESCRIPTION
Tapazole Methimazole Tablets, USP DESCRIPTION TAPAZOLE (Methimazole Tablets, USP) (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. It differs chemically from
More informationThe Effect of Anti Thyroid Medications on the Therapeutic outcome of I-131 in Hyperthyroid Patients with Graves ' disease
Original Paper, Endocrine. The Effect of Anti Thyroid Medications on the Therapeutic outcome of I-131 in Hyperthyroid Patients with Graves ' disease Younis, J. Oncology and Nuclear Medicine Department,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationA case of metastatic follicular thyroid carcinoma complicated with Graves disease after total thyroidectomy
2017, 64 (12), 1143-1147 Original A case of metastatic follicular thyroid carcinoma complicated with Graves disease after total thyroidectomy Mariko Aoyama 1), Hiromitsu Takizawa 1), Mitsuhiro Tsuboi 1),
More informationANTITHYROID drugs are effective in controlling
220 THE NEW ENGLAND JOURNAL OF MEDICINE Jan. 25, 996 LACK OF EFFECT OF THYROXINE IN PATIENTS WITH GRAVES HYPERTHYROIDISM WHO ARE TREATED WITH AN ANTITHYROID DRUG BRYAN MCIVER, M.B., CH.B., PETER RAE, M.B.,
More informationGranulocyte-macrophage colonystimulating factors (G-CSF) Treatment for Severe Congenital Neutropenia (SCN)
Granulocyte-macrophage colonystimulating factors (G-CSF) Treatment for Severe Congenital Neutropenia (SCN) Introduction Definitions - Neutropenia absolute neutrophil count (ANC)
More informationNobuyuki Takasu, Haruyo Higa and Yoshino Kinjou. Abstract
CASE REPORT Treatment of Pretibial Myxedema () with Topical Steroid Ointment Application with Sealing Cover (Steroid Occlusive Dressing Technique: Steroid ODT) in Graves Patients Nobuyuki Takasu, Haruyo
More informationDrug-Induced Vasculitis
Drug-Induced Vasculitis Shelly Rivas, Amit G. Pandya, and Arturo R. Dominguez 8 Abstract Drug-induced vasculitis is defined as inflammation of blood vessels due to an adverse effect of a drug. Histologically,
More informationAntithyroid drugs (ATD) have been in use since 1946
THYROID Volume 25, Number 12, 2015 ª Mary Ann Liebert, Inc. DOI: 10.1089/thy.2014.0603 REVIEWS and SCHOLARLY DIALOG Antineutrophil Cytoplasmic Antibody Positive Small-Vessel Vasculitis Associated with
More informationHyperthyroidism. Causes. Diagnosis. Christopher Theberge
Hyperthyroidism Pronunciations: (Hyperthyroidism) Hyperthyroidism (overactive thyroid) is a condition where the thyroid gland synthesizes and secretes the thyroid hormones thyroxine (T4) and triiodothyronine
More informationDepartment of Internal Medicine II, Kansai Medical University, Osaka , Japan 9)
2016, 63 (1), 1-10 OPINION Advance Publication doi: 10.1507/endocrj.EJ16-0336 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition)
More informationPropylthiouracil-Associated Antineutrophil. Cytoplasmic Antibodies Resulted. Microscopic Polyangiitis and. Pulmonary-Renal Syndrome
2005 16 230-235 Propylthiouracil-Associated Antineutrophil Cytoplasmic Antibodies Resulted Microscopic Polyangiitis and Pulmonary-Renal Syndrome A Case Report and Literature Review Chin-Chung Shu, Shuen-Fu
More informationHyperthyroidism Diagnosis and Treatment. April Janet A. Schlechte, M.D.
Hyperthyroidism Diagnosis and Treatment Family Practice Refresher Course April 2015 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any
More informationThe Effect of Anti Thyroid Medications on the Therapeutic outcome of I-131 in Hyperthyroid Patients with Graves ' disease
Original Paper, Endocrine. The Effect of Anti Thyroid Medications on the Therapeutic outcome of I-131 in Hyperthyroid Patients with Graves ' disease Younis, J. Oncology and Nuclear Medicine Department,
More informationCytoplasmic Anti-Neutrophil Cytoplasmic Antibody Positive Diffuse Alveolar Hemorrhage Associated with Methimazole
pissn: 2093-940X, eissn: 2233-4718 Journal of Rheumatic Diseases Vol. 24, No. 4, August, 2017 https://doi.org/10.4078/jrd.2017.24.4.236 Case Report Cytoplasmic Anti-Neutrophil Cytoplasmic Antibody Positive
More informationUse of Antihistamines After Serious Allergic Reaction to Methimazole in Pediatric Graves Disease
CASE REPORT Use of Antihistamines After Serious Allergic Reaction to Methimazole in Pediatric Graves Disease AUTHORS: Amy B. Toderian, BSc a and Margaret L. Lawson, MD, MSc, FRCP b a Faculty of Medicine,
More informationNew Guidelines for the Management of Graves Hyperthyroidism
New Guidelines for the Management of Graves Hyperthyroidism International Guidelines in Thyroid Disease in Daily Practice Vienna, Austria June 8-9, 2012 Rebecca Bahn Mayo Clinic Rochester, MN USA ATA/AACE
More informationRituximab treatment for ANCA-associated vasculitis in childhood
Rituximab treatment for ANCA-associated vasculitis in childhood DISCLOSURE I have no relevant financial relationships to disclose Katharine Moore MD Nov 14, 2012 University of Colorado School of Medicine
More informationSweet s Syndrome Associated with Graves Disease
C A S E REPORT pissn: 2384-3799 eissn: 2466-1899 Int J Thyroidol 2017 May 10(1): 50-55 https://doi.org/10.11106/ijt.2017.10.1.50 Sweet s Syndrome Associated with Graves Disease Ho Jin Yong 1, Mi Il Kang
More informationThyroid Hormones (T 4 & T 3 )
1 Thyroid Hormones (T 4 & T 3 ) Normalize growth and development, body temperature, and energy levels. Used as thyroid replacement therapy in hypothyroidism. Thyroxine (T 4 ) is peripherally metabolized
More informationPLACE OF SELENIUM IN THE TREATMENT OF THYROID DISEASES
VII, 2013, 2 27, PLACE OF SELENIUM IN THE TREATMENT OF THYROID DISEASES D. Gavrailova Faculty of Public Health, Medical University So a : (Se).,. Se, - (, )., Se., Se -. :,,, :,, Summary: The essential
More informationAN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS
GRANULOMATOSIS WITH POLYANGIITIS (GPA), MICROSCOPIC POLYANGIITIS (MPA), and EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS What is ANCA-associated Vasculitis?
More informationStress Doses of Glucocorticoids Cannot Prevent Progression of All Adrenal Crises
Clin Pediatr Endocrinol 2009; 18(1), 23-27 Copyright 2009 by The Japanese Society for Pediatric Endocrinology Original Article Stress Doses of Glucocorticoids Cannot Prevent Progression of All Adrenal
More informationContext: Thionamides have various side effects.
SPECIAL FEATURE Extensive Clinical Experience Remission After Potassium Iodide Therapy in Patients With Graves Hyperthyroidism Exhibiting Thionamide-Associated Side Effects Ken Okamura, Kaori Sato, Megumi
More informationAnti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease
Anti-MPO ANCA-Associated Diffuse Alveolar Hemorrhage is Associated with Increased Mortality Compared to Anti-PR3 Disease Grace M. Lee, Yara A. Park, Marshall Mazepa, Jay S. Raval Introduction Anti-neutrophil
More informationA retrospective cohort study: do patients with graves disease need to be euthyroid prior to surgery?
Al Jassim et al. Journal of Otolaryngology - Head and Neck Surgery (2018) 47:37 https://doi.org/10.1186/s40463-018-0281-z ORIGINAL RESEARCH ARTICLE Open Access A retrospective cohort study: do patients
More informationMethimazole Treatment of 262 Cats With Hyperthyroidism
Methimazole Treatment of 262 Cats With Hyperthyroidism Mark E. Peterson, DVM, Peter P. Kintler, DVM, and Arthur I. Hurvitz, CVM, PhD The efficacy and safety of the antithyroid drug methimazole were evaluated
More informationThyroid Storm: Uncommon Presentation. Noora M. Butti, MBBcH*
Bahrain Medical Bulletin, Vol. 36, No. 3, September 2014 Thyroid Storm: Uncommon Presentation Noora M. Butti, MBBcH* Thyroid storm could lead to mortality; it is rare and characterized by severe clinical
More informationAutoimmune diagnostics. A comprehensive product line for the detection of autoantibodies
Autoimmune diagnostics A comprehensive product line for the detection of autoantibodies Autoimmune diagnostics Autoimmune diseases are chronic inflammatory processes with an indeterminate etiology. They
More informationSmall Vessel Vasculitis
Banff- Rocky Mountain Barry Kassen, MD, FRCPC,FACP Head, Division of Internal Medicine UBC/VGH/SPH Acting Head, Division of Community Internal Medicine November, 2009 Objectives 1. To understand small
More informationAssociation of the Ultrasonographic Findings of Subacute Thyroiditis with Thyroid Pain and Laboratory Findings
Endocrine Journal 2008, 55 (3), 583 588 Association of the Ultrasonographic Findings of Subacute Thyroiditis with Thyroid Pain and Laboratory Findings NARIKO OMORI, KAZUE OMORI AND KAZUE TAKANO Department
More informationThe Major Histocompatibility Complex (MHC)
The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens
More informationMASATERU HORIMOTO, MITSUSHIGE NISHIKAWA, CHISATO UNO, NoRIO YOSHIKAWA, NORIMICHI TANIGUCHI AND MITSUO INADA
Relationship among Thyrotropin (TSH), Thyroid Stimulating Immunoglobulins, and Results of Triiodothyronine (T3) Suppression Test in Patients with Graves' Disease MASATERU HORIMOTO, MITSUSHIGE NISHIKAWA,
More informationHepatitis-Associated Aplastic Anemia. Kazuko KUDO and Seiji KOJIMA Department of Pediatrics, Nagoya University Graduate School of Medicine
Hepatitis-Associated Aplastic Anemia Kazuko KUDO and Seiji KOJIMA Department of Pediatrics, Nagoya University Graduate School of Medicine Abstract We retrospectively analysed the clinical outcome of 85
More informationTwo types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis
Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis M. Yoshida, M. Sasaki, I. Nakabayashi, M. Akashi, T. Tomiyasu,
More informationFULL PAPER THERAPEUTIC RESPONSE EVALUATION ON HYPERTHYROIDISM USING A FIXED DOSED OF I-131
FULL PAPER THERAPEUTIC RESPONSE EVALUATION ON HYPERTHYROIDISM USING A FIXED DOSED OF I-131 Yulia Kurniawati, and AHS Kartamihardja Department of Nuclear Medicine, Dr. Hasan Sadikin General Hospital, Faculty
More informationA Dual-Fixed Neutrophil Substrate Improves Interpretation of Antineutrophil Cytoplasmic Antibodies by Indirect Immunofluorescence
AJCP / Original Article A Dual-Fixed Neutrophil Substrate Improves Interpretation of Antineutrophil Cytoplasmic Antibodies by Indirect Immunofluorescence Ming-Wei Lin, MBBS, 1,2 Roger A. Silvestrini, 1
More informationA 2017 SURVEY OF THE CLINICAL PRACTICE PATTERNS IN THE MANAGEMENT OF RELAPSING GRAVES DISEASE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationANCA associated vasculitis in China
ANCA associated vasculitis in China Min Chen Renal Division, Peking University First Hospital, Beijing 100034, P. R. China 1 General introduction of AAV in China Disease spectrum and ANCA type Clinical
More informationThyroid in the elderly. Akbar Soltani M.D. Endocrinology and Metabolism Research Center (EMRC) Shariati Hospital
Thyroid in the elderly Akbar Soltani M.D. Endocrinology and Metabolism Research Center (EMRC) Shariati Hospital soltania@tuma.ac.ir Case 1 A 79 year old female is seen because of a 6 month history of fatigue,
More informationRapid Differential Diagnosis of Graves Disease and Painless Thyroiditis Using Total T3/T4 Ratio, TSH, and Total Alkaline Phosphatase Activity
Endocrine Journal 2005, 52 (1), 29 36 Rapid Differential Diagnosis of Graves Disease and Painless Thyroiditis Using Total T3/T4 Ratio, TSH, and Total Alkaline Phosphatase Activity TETSUO YANAGISAWA, KANJI
More informationVASCULITIS PRODUCT HIGHLIGHTS
VASCULITIS PRODUCT HIGHLIGHTS AESKU.DIAGNOSTICS offers a comprehensive and complete diagnostic portfolio in the field of vasculitis diagnostics. Not only are screening and profiling s available but also
More informationCanadian Endocrine Review Course 2014
Canadian Endocrine Review Course 2014 Amiodarone & Thyrotoxicosis Iodine, A Catch 22 Ally P.H. Prebtani Associate Professor of Medicine Internal Medicine, Endocrinology & Metabolism McMaster University
More informationBELIEVE MIDWIFERY SERVICES
TITLE: THYROID DISEASE IN PREGNANCY EFFECTIVE DATE: July, 2013 POLICY STATEMENT: Pregnancy changes significantly the values influenced by the serum thyroid binding hormone level (i.e., total thyroxine,
More informationOriginal. Advance Publication doi: /endocrj. EJ Endocrine Journal 2015
Endocrine Journal 2015 Original Advance Publication doi: 10.1507/endocrj. EJ15-0157 Distribution of serum immunoglobulin G4 levels in Hashimoto s thyroiditis and clinical features of Hashimoto s thyroiditis
More informationGRAVES DISEASE is the commonest form of hyperthyroidism,
0021-972X/00/$03.00/0 Vol. 85, No. 3 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Age and Gender Predict the Outcome of Treatment for Graves
More informationPRODUCT INFORMATION. NEO-MERCAZOLE (carbimazole)
PRODUCT INFORMATION NEO-MERCAZOLE (carbimazole) NAME OF MEDICINE Carbimazole (CAS registry number: 22232-54-8) O O N S N CH 3 The chemical name for carbimazole is ethyl 3 methyl-2-thioxo-4-imidazoline-1-carboxylate.
More informationPRESCRIBING INFORMATION PROPYL-THYRACIL. (propylthiouracil tablets USP) Thyroid Inhibitor
PRESCRIBING INFORMATION PROPYL-THYRACIL (propylthiouracil tablets USP) Thyroid Inhibitor Paladin Labs Inc. Date of Revision: 6111 Royalmount Avenue, Suite 102 June 25, 2013 Montreal, Quebec Version : 5.0
More informationA RARE CASE OF THYROTOXICOSIS IN PEDIATRIC PRACTICE
Original Case Report DOI - 10.26479/2016.0204.13 A RARE CASE OF THYROTOXICOSIS IN PEDIATRIC PRACTICE Renata Markosyan 1,2, Natalya Volevodz 3,4, Lusine Navasardyan 1,2 and Karmella Pogosyan 2 1.Yerevan
More informationNeupogen (Filgrastim)/Neulasta (Pegfilgrastim)
Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationReview Article Management of Hyperthyroidism in Pregnancy: Comparison of Recommendations of American Thyroid Association and Endocrine Society
Thyroid Research Volume 2013, Article ID 878467, 6 pages http://dx.doi.org/10.1155/2013/878467 Review Article Management of Hyperthyroidism in Pregnancy: Comparison of of American Thyroid Association and
More informationSTARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.
STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management
More informationA Case of Propylthiouracil-associated Antineutrophil Cytoplasmic Antibody Development
CLINICAL VIGNETTE A Case of Propylthiouracil-associated Antineutrophil Cytoplasmic Antibody Development Rebecca Weiss, MD, Sonia R. Grewal, MD and Dorothy S. Martinez, MD Abstract The development of positive
More informationKENJI MORIYAMA, TAKASHI AKAMIZU, MITSUYOSr UMEMOTO, MASAxo MIURA, MISA SAIJO,
Endocrine Journal 1999, 46 (5), 687-693 A Case of Hashimoto's Thyroiditis with Markedly Elevated Serum Thyroglobulin and Evidence of its Influence on the Measurement of Anti-Thyroglobulin Antibody by Highly
More informationImmune tolerance, autoimmune diseases
Immune tolerance, autoimmune diseases Immune tolerance Central: negative selection during thymic education deletion of autoreactive B-lymphocytes in bone marrow Positive selection in the thymus Negative
More information